With over 50 years of industry experience, we support pharmaceutical and biotechnology companies worldwide by delivering custom peptide synthesis, oligonucleotide manufacturing, and GMP-compliant production services.
Our unique corporate culture is built on collaboration, transparency, and strategic partnerships—both internally and with customers, suppliers, and global stakeholders. We foster an open, team-driven environment powered by innovation, advanced technology, and continuous improvement, while maintaining a strong reputation for reliability, quality, and solution-oriented execution.
Driven by a passion for scientific progress, we are committed to helping our partners accelerate medical breakthroughs and develop innovative therapies that improve patient outcomes worldwide. Enabling the advancement of next-generation pharmaceutical treatments is the mission that inspires us every day.
board of directors
Kuno Sommer
CEO / Founder
Dr. Kuno Sommer, Ph.D. University of Basel, worked for Roche from 1986 to 1999 in various functions, including four years in the USA. Kuno Sommer was ultimately a member of the Executive Committee of Roche, responsible for the Flavours and Fragrances division, today Givaudan. From 2000 to 2006 he was CEO of Berna Biotech. Kuno Sommer is Chairman of the Board of Sunstar-Holding AG, of Kenta Biotech AG, of TargImmune Therapeutics AG and, until Septem-
ber 1, 2023, of Infors AG as well as member of the Board of Directors of Spexis AG..
Steffen Lang
Vice chairman
Dr. Steffen Lang has been President of Novartis Operations since 2022. He is a member of the Executive Committee of Novartis. Prior to his current appointment, Steffen Lang served as Global Head Novartis Technical Operations from 2017 to 2022. He joined Novartis in 1994 as Head of Laboratory in Research, and over the years has held various positions within Pharmaceuticals Development and Technical Operations. Mr. Lang holds a doctorate in pharmaceutical technology from the Swiss Federal Institute of Technology (ETHZ), and a degree in pharmaceutical sciences from the University of Heidelberg in Germany.
Alex Fallser
member
Dr. Alex Fässler began his industrial career at Ciba-Geigy, later Novartis, where he held various positions in preclinical Research in Basel, New Jersey and England. He joined Bachem AG in 1998, and thereafter served as Head of Production in the US subsidiary, site manager and finally as regional COO for the Americas. After his return to Switzerland in 2013 he was appointed COO of Bachem Europe, and from 2017 to 2018 he held the function of COO of the Bachem Group, and was a member of the Corporate Executive Committee.
Simone Wyss Fedele
member
Dr. Simone Wyss Fedele has been CEO of Switzerland Global Enterprise (S-GE), the official Swiss organization for export and investment promotion, since 2019, where she intermittently also held the role of CFO. She is designated for the chairmanship of the S-GE Board of Directors and is currently a member of the WEF Global Future Councils on International Trade and Investment. Before, she was Chief Economist and Head of Public Affairs at Novartis International in Switzerland. Prior to that, she was Commercial Lead and Head of Market Access for Europe and Canada at Takeda Pharmaceuticals. She holds a doctorate in international economics from the University of Basel.